Terms: = Leukemia AND CIITA, P33076, 4261, ENSG00000179583, MHC2TA, C2TA AND Treatment
6 results:
1. Prognostic and clinicopathological significance of PD-1/PD-L1 expression in the tumor microenvironment and neoplastic cells for lymphoma.
Xie M; Huang X; Ye X; Qian W
Int Immunopharmacol; 2019 Dec; 77():105999. PubMed ID: 31704289
[TBL] [Abstract] [Full Text] [Related]
2. CML cells actively evade host immune surveillance through cytokine-mediated downregulation of MHC-II expression.
Tarafdar A; Hopcroft LE; Gallipoli P; Pellicano F; Cassels J; Hair A; Korfi K; Jørgensen HG; Vetrie D; Holyoake TL; Michie AM
Blood; 2017 Jan; 129(2):199-208. PubMed ID: 27793879
[TBL] [Abstract] [Full Text] [Related]
3. Epigenetic modification and preliminary investigation of the mechanism of the immune evasion of HL-60 cells.
Liu JH; Bian YM; Xie Y; Lu DP
Mol Med Rep; 2015 Jul; 12(1):1059-65. PubMed ID: 25815463
[TBL] [Abstract] [Full Text] [Related]
4. Defective class II transactivator expression in a B lymphoma cell line.
Prod'homme T; Drénou B; De Ruyffelaere C; Barbieri G; Wiszniewski W; Bastard C; Charron D; Alcaide-Loridan C
Leukemia; 2004 Apr; 18(4):832-40. PubMed ID: 14973505
[TBL] [Abstract] [Full Text] [Related]
5. Regulation of MHC class II expression in human T-cell malignancies.
Holling TM; Schooten E; Langerak AW; van den Elsen PJ
Blood; 2004 Feb; 103(4):1438-44. PubMed ID: 14563641
[TBL] [Abstract] [Full Text] [Related]
6. Differences in teniposide disposition and pharmacodynamics in patients with newly diagnosed and relapsed acute lymphocytic leukemia.
Evans WE; Rodman JH; Relling MV; Petros WP; Stewart CF; Pui CH; Rivera GK
J Pharmacol Exp Ther; 1992 Jan; 260(1):71-7. PubMed ID: 1731053
[TBL] [Abstract] [Full Text] [Related]
